Navigation Links
Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007

DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeutics today announced the presentation of data on the immunosuppressive properties of soluble CD83 at the 7th Joint American Transplant meeting to be held in San Francisco, May 5-9. The presentations will be made in collaboration with scientists at the University of Western Ontario.

"These data suggest that soluble CD83 is able to extend graft survival in transplantation, and that it can also act synergistically with other immunosuppressive agents," commented Dr. Stephen Brand, Director of Biotherapeutics at Argos Therapeutics. "sCD83 appears to be able to maintain antigen presenting cells in an immature state, and these immunologically tolerant cells favor regulatory T-cell generation because they are less effective in activating naive T and B cells."

"This emerging activity profile for sCD83, as well as its ability to suppress antibody production without systemic suppression, may provide advantages over currently available B-cell targeting therapies," said Dr. Charles Nicolette, Chief Scientific Officer and Vice President of Research and Development of Argos. "The extended graft survival that we have observed thus far indicates that sCD83 could potentially provide enhanced organ function, without immune rejection, and may serve to reduce the toxic profile associated with many commonly used immunotherapeutic agents. These data support Argos' plans to conduct additional studies with CD83 in transplantation and autoimmune models, which will provide important information as we develop a clinical strategy for this candidate."

Data will be discussed in the following presentations:

-- Abstract # 1697: "Soluble CD83 in combination with Rapamycin and anti-CD45RB monoclonal antibody induces long-term graft survival in a mouse cardiac transplantation model"

-- Abstract #116: "Soluble CD83 can inhibit B-cell activation and differentiati
'"/>




Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:12/19/2014)... -- TODAY, AEGATE, the leader in medicine ... appointment of Peter Fox as Chief Technology ... Partner Officer. Peter has served as Development ... by Oracle in 2011. Prior to Datanomic, ... and subsequently Convergys, a world renowned billing system ...
(Date:12/19/2014)... BOCA RATON, Fla. , Dec. 19, 2014 /PRNewswire/ ... entered into a multi-product agreement with MSN Laboratories Pvt. ... Breckenridge and MSN expect to commercialize several new ANDAs. ... manufacture, and supply the products exclusively to Breckenridge for ... the products under its label.  Breckenridge and MSN have ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. (OTCQB: ... Corp.) is pleased to provide this review of the ... in 2015. "Over this past year, we ... I am extremely proud to say that Monarch America ... than it has ever been," stated Eric Hagen ...
Breaking Medicine Technology:Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
... MYL ) today announced that it has notified The ... (Nasdaq: NDAQ ), that it intends to voluntarily de-list ... Market, on which the notes trade under the ticker symbol "MYLNG," ... The notes will continue to trade over-the-counter (OTC) with trade data ...
... Ultra Clean Holdings, Inc. (Nasdaq: UCTT ), ... semiconductor capital equipment, medical device, energy, research, and flat ... Executive Officer, and Casey Eichler, Chief Financial Officer, will ... will take place at the New York Palace Hotel, ...
Cached Medicine Technology:Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq 2
(Date:12/21/2014)... 2014 Hundreds of Byetta lawsuits ... involving a class of Type 2 diabetes drugs ... in a federal multidistrict litigation now underway in ... Liebhard LLP reports. According to an Order dated ... cut-off date of February 27, 2014 for discovery ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Serious Buyer, ... for Vintage 1967 Jm Morrison and the Doors International Ballroom ... This would also be the only time that Morrison's ... was on Nov. 25, 1967. According to Hawley, “This ... They did play the Alexandria Roller Rink earlier that ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... and blood clots from using testosterone products such as ... shows that the male hormone testosterone may increase the ... published in the Proceedings of the National Academy of ... group of male rats with naturally occurring colon cancer. ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly bamboo flooring ... bamboo flooring promotion for the coming 2015. , ... and offers the best bamboo products and services ... all customers can enjoy a special discount, up ... BambooIndustry.com from press releases. , The bamboo flooring ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4
... California, San Diego (UCSD) School of Medicine, liver cancer ... death and renewal – liver cell proliferation. ... in advance of publication in the journal Proceedings of ... JNK1-mediated cell death and compensatory proliferation. The findings by ...
... reported that there appears to be three variations of ... on humans upon their susceptibility towards tuberculosis// . Researchers ... to why some patients infected with the Mycobacterium tuberculosis ... not affected. The findings was published in the online ...
... that has twice the amount of oleic acid found in ... //is being tested by researchers at the Iowa State University ... oil can go where no unhydrogenated soybean oil has gone ... sauces and non-dairy creamers) that require more stability than previous ...
... Reddy's Laboratories today announced that it has launched the authorized ... June 19. // ,The company has also launched ... mg, 10 mg, 20 mg, 40 mg and 80 mg ... year, the company entered into separate agreements with Merck that ...
... habits can help lessen the intensity of migraines, says ... neurology //at the University of North Carolina Medical School, ... who improved their sleep habits had reduced headache frequencies. ... headache frequency by 29 percent and headache intensity by ...
... fund raisers are taking part in the moon walk which will ... walk along with the famous TV star Lorraine Kelly. ... one million pounds for breast cancer and the Maggie’s Centre. They ... the day of the event. ,Hence the name Moon ...
Cached Medicine News:Health News:Repeated Liver Cell Proliferation, a Cause for Liver Cancer 2Health News:Susceptibility Of TB In Humans Might Be Due To Three Human Gene Variants 2Health News:New Variety Of Soybean Oil 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: